Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 16/20 | 0.47 |
| ▸ | WDR77 | Q9BQA1 | 16/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | FPR2 | P25090 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29081527 | 1.00 | PRMT5 (0.47) | PRMT5WDR77ATMHCAR2MAPT | |
| SCHEMBL1531663 | 0.81 | HCAR2 (0.53) | PRMT5WDR77ATMHCAR2MAPT | |
| SCHEMBL31311343 | 0.79 | HSD17B10 (0.53) | PRMT5WDR77ATMHCAR2MAPT | |
| SCHEMBL7668126 | 0.79 | HSD17B10 (0.53) | PRMT5WDR77ATMHCAR2MAPT | |
| SCHEMBL18481112 | 0.79 | L3MBTL1 (0.52) | PRMT5WDR77ATMHCAR2MAPT | |
| SCHEMBL13778299 | 0.79 | ALDH1A1 (0.47) | PRMT5WDR77ATMHCAR2MAPT | |
| SCHEMBL17382220 | 0.78 | KIF11 (0.47) | PRMT5WDR77ATMHCAR2MAPT | |
| SCHEMBL24363890 | 0.76 | PRMT5 (0.51) | PRMT5WDR77ATMHCAR2 | |
| SCHEMBL29325505 | 0.76 | PRMT5 (0.51) | PRMT5WDR77ATMHCAR2MAPT | |
| SCHEMBL24233791 | 0.76 | SIRT2 (0.48) | PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12304907-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| EP-4188920-A1 | PIPERIDIN-1-YL-N-PYRYDINE-3-YL-2-OXOACETAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MTA-ACCUMULATING CANCERS | Tango Therapeutics, Inc. (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20230113778-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| US-11492350-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2022-11-08 | — | — | US | disclosed |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | PRMT5 347/4885WDR77 1263/4885ATM 3957/4885 |
| US-11492350-B2 | Compounds and methods of use | F12, C1R, ABCG2 | PRMT5 347/4885WDR77 1263/4885ATM 3957/4885 |
| US-20230113778-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | PRMT5 347/4885WDR77 1263/4885ATM 3957/4885 |
| US-12304907-B2 | Compounds and methods of use | F12, C1R, ABCG2 | PRMT5 347/4885WDR77 1263/4885ATM 3957/4885 |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | PRMT5 347/4885WDR77 1263/4885ATM 3957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.